CeBIL is international and interdisciplinary. Anchored at the Faculty of Law, the Centre is led by founding director Professor Timo Minssen. CeBIL collaborates with key national and international experts from academia, public bodies, patient organizations and industry. Some of the most renowned international academic capacities in biomedical innovation law are involved in the CeBIL-program as either Core Partners or Collaborators. The Core Partners of the CeBIL-program are listed below.
Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) at the Faculty of Law
Department of Food and Resource Economics (IFRO), UCPH
|Centre for Law, Medicine and Life Sciences, University of Cambridge
Director, Dr. Kathleen Liddell contributes with expertise on intellectual property rights, patents and translational medicine. In addition, Professor Lionel Bentley (IP, trademarks, patents), Dr. Jeffrey Skopek (ethics, big data, personalised medicine), Dr. Stuart Hogarth (empirical studies, biomedical innovation, regulatory governance) and Dr. Mateo Aboy (biomedical engineering, patents, IP landscaping big data) participates and contributes to CeBIL.
| Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics, Harvard Law School
Faculty Director, Professor I.G. Cohen. Cohen contributes with expertise on the intersection of bioethics/medical ethics and the law with a specific focus on big data, policy and translational medicine.
|PORTAL - Program on Regulation, Therapeutics and Law, Harvard Medical School and Brigham & Women’s Hospital
Head of PORTAL, Professor Aaron Kesselheim, along with his team, Dr. Michael Sinha and Dr. Jonathan Darrow, contributes with both medical and legal expertise in relation to a.o. antibiotics, pharmaceutical development, and patents.
|University of Michigan Law School
Dr. Nicholson Price contributes with special expertise in drug manufacturing, patent law, regulatory governance, health law, personalized medicine, big data.